Allergan rides high on patent backing for key drugs Lumigan and Restasis

Carly Helfand Patent-cliff worries have been weighing on Allergan as of late, but a Texas judge has allayed some of those concerns–at least for now. That judge upheld ...

Aduro’s combo cancer vaccine combo posts positive survival benefits

John Carroll About three years ago Aduro BioTech licensed in the failed cancer vaccine GVAX from BioSante with a plan to study it in combination with its own CRS-207 to see if the one-two ...

Busy Regeneron busts Eylea sales forecasts, re-ups with Sanofi

Tracy Staton Yesterday, Regeneron CEO Len Schleifer announced that rather than the $ 377 million expected by analysts, Regeneron will report about $ 400 million in U.S. sales for macular ...

Bristol-Myers says it’s open to dealmaking in the cancer field

Emily Mullin Bristol-Myers Squibb says it's on the lookout for new deals, but that its focus will be on snapping up experimental treatments still in development instead of commercial ...

Merck recall depletes supplies of new cholesterol drug

Eric Palmer Merck & Co.'s Liptruzet has only been on the market since last May, but it will soon be unavailable. The drugmaker is asking wholesalers to return all lots they ...

Roche’s dealmakers at pRED will continue their global shopping spree in 2014

John Carroll Over the past year John Reed has been tasked with engineering a turnaround at Roche's big pRED research organization, executing a string of new deals aimed at beefing ...

Drug buyers sue Novo Nordisk over ‘wrongful’ delays to diabetes generic

Carly Helfand The Federal Trade Commission may now have the right to challenge pay-for-delay deals, but drugmakers can still stall the launches of competing generic products. And that's ...

For its next trick, Moderna splits in two with $20M cancer venture

Damian Garde Moderna Therapeutics has chosen the big stage of the JPMorgan conference to unveil its next gambit: splitting in two and launching a standalone company to advance ...

Celgene looks to double its sales by 2017 on wave of cancer drug growth

Tracy Staton Celgene figures it will end 2014 with $ 7.4 billion in net sales, adding about $ 1 billion to its $ 6.4 billion total for 2013. But by 2017, the company figures it will ...

Lilly buys back a migraine therapy from Arteaus Therapeutics

Emily Mullin Eli Lilly has struck a deal with Arteaus Therapeutics to acquire the Cambridge, MA-based company's migraine therapy being studied in a Phase II clinical trial. FierceBiotech ...

C-suite shuffle: Amgen CFO Peacock resigns

Eric Palmer The company named Michael Kelly, an 11-year Amgen veteran, to hold the CFO position on an interim basis. FiercePharma News

Amgen spinoff Atara cranks its Series B up to $52M

Damian Garde California's Atara Biotherapeutics has heaped more cash onto its second funding round, giving the Amgen spinoff $ 52 million in Series B funds to support its programs ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS